updat model reflect close aet well slightli higher
pro-forma tax rate lower est slightli lower pt despit
continu believ share current underappreci strateg valu cvs-aet
also see upsid est greater expect synergi well revenu
synergi management quantifi yet
remain one favorit name coverag continu believ
current valuat consider undervalu strateg valu uniqu suit
asset includ legaci retail pharmaci pharmaci benefit busi along
insur busi acquir via aet despit management expect
slightli higher tax rate proforma-basi compar stand-alon
lower estim price target unlik integr model
advantag frequent conveni interact patient retail
pharmaci locat well minuteclin cvss focu coordin care chang
patient behavior better manag chronic condit elimin wast healthcar
spend could result greater margin enterpris well competit
price patient manag believ could result share gain time
furthermor see upsid management updat target greater synergi
well upsid revenu synergi explicitli assum model
yet quantifi management
given management expect acquisit aet close prior thanksgiv
updat model reflect close model stand-alon conform
management stand-alon guidanc sake simplic assum one-month
contribut aet addit assum one month pro-forma interest expens
interest expens consist management expect slight
increas tax rate pro-forma basi stand-alon rais tax
rate lastli assum issuanc share aet sharehold
rais share count result assumpt adj
ep estim compar stand-alon estim in-line
management expect transact dilut adj ep
lower adj ep estim
respect lower estim result close transact
dilut impact lower estim larg due higher tax
rate given management expect also slightli lower price target
base revis dcf analysi impli share trade
pro-forma adj ep estim current
pleas see page report import disclosur
current invest thesi lie acquisit aet view favor
think care coordin combin entiti posit well value-bas
care believ differenti model like lead best outcom lower cost
manag chronic condit use minuteclin leverag telemedicin
non-physician provid addit share look under-valued current level pro
forma basi rel peer pharma suppli chain manag care
 progress regulatori approv
process pend acquisit aet
 close aet
 top-lin growth retail/ltc
revenu pbm revenu
one month contribut aet
 oper margin modestli
y/i due increment oper expens
reinvest mix shift toward
pbm segment
 assum share repo
 assum one month contribut aet
 strong retail comp better macro
environ coupl better pbm
 stronger gener lower
 later expect close aet
transact dilut impact
 slower expect growth
 weaker expect gener
greater expect reimburs
 sooner expect close aet
transact dilut impact
one largest drug retail chain compani larg oper
two main busi segment pharmaci servic retail pharmaci
retail pharmaci segment compani oper drugstor on-line retail
pharmaci websit well health clinic store sell prescript drug
wide array gener merchandis refer front end product
compani also provid full rang pbm servic client mainli includ
organ sponsor health benefit plan servic includ formulari
servic diseas manag program pharmacogenom servic
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang net work terminal- valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per-shar data
compani report cowen compani
interseg net good interseg net cost good gross gross chang oper oper chang intang interest expens expenses- pre-tax pre-tax chang adj incom tax provis effect tax net adj net incom chang earn alloc particip net incom attribut non-controlling adj net incom attribut intang loss earli extinguish debt- loss discontinu operations- net loss non-controlling acquisition-rel financ non-recur net weight averag dilut share adj ebitda chang chang y/i net net incom attribut end decemb cowen
million except per-shar data
compani report cowen compani
interseg net good interseg net cost good gross gross chang oper oper chang intang interest expens pre-tax pre-tax chang adj incom tax provis effect tax net adj net incom chang earn alloc particip net incom attribut non-controlling adj net incom attribut intang loss earli extinguish debt- loss discontinu operations- net loss non-controlling acquisition-rel financ non-recur net weight averag dilut share adj ebitda chang chang y/i net net incom attribut cowen
million
compani report cowen compani
cash short-term account receiv defer incom current current properti equip intang asset total liabil account claim discount accru short-term debt- current portion long-term current long-term defer incom non-curr redeem non-controlling stockhold equiti common treasuri share held capit retain accumul comprehens total health sharehold non-controlling total sharehold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti decemb cowen
million
compani report cowen compani
income/ loss adjust requir reconcil net incom net cash provid oper activ depreci goodwil loss settlement defin benefit pension stock-bas defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv current account payabl claim discount accru long-term net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur exclud non-recur itemsyear end decemb cowen
million
compani report cowen compani
activitiesnet adjust requir reconcil net incom net cash provid oper activ depreci goodwil impairments- loss settlement defin benefit pension plans- stock-bas loss earli extinguish defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv current account payabl claim discount accru long-term net cash provid oper invest activitiespurchas properti proce sale-lease-back proce sale properti equip acquisit net cash acquir purchas available-for-sal sale matur available-for-sal net cash use invest financ activitiesincreas decreas short-term proce issuanc long-term repay long-term purchas non-controlling interest subsidiary- payment conting consideration- dividend proce exercis stock payment tax relat net share settlement equiti repurchas common other- net cash provid use financ effect exchang rate net decreas cash cash cash equival begin cash equival end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
lack regulatori approv acquisit aet challeng
slower expect onboard contract
